AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18076218
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate with pantoprazole 40 mg twice daily starting 2 days prior to dabigatran administration
Trial: 14559386
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered allopregnanolone gel during the last 10 days of the second cycle (group 1)
Trial: 14559386
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered allopregnanolone gel during the last 10 days of each cycle (group 2)
Trial: 3533126
Drug: Methylprednisolone (84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (84 mg total over 4 days, starting with 24 mg 2 hours after surgery)
Trial: 3533126
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g at 2, 6, and 9 hours after surgery, then 500 mg four times daily for the next 2 days)
Trial: 24363128
Drug: CyA MEPC
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA MEPC 2-3 mg/kg BW once a day before breakfast
Trial: 24363128
Drug: CyA MEPC
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA MEPC 1.5 mg/kg BW twice a day before meals
Trial: 24363128
Drug: CyA MEPC
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA MEPC 2-3 mg/kg BW once a day (C2 ≥600 ng/mL)
Trial: 24363128
Drug: CyA MEPC
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA MEPC 1.5 mg/kg BW twice a day (C2 ≥600 ng/mL)
Trial: 20886571
Drug: Standard-dose pregabalin/tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose pregabalin/tolterodine ER (150 mg BID/4 mg QD)
Trial: 20886571
Drug: Pregabalin alone
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin alone (150 mg BID)
Trial: 20886571
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER alone (4 mg QD)
Trial: 20886571
Drug: Low-dose pregabalin/tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose pregabalin/tolterodine ER (75 mg BID/2 mg QD)
Trial: 19723121
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tonabersat
Trial: 19723121
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tonabersat
Trial: 19723121
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sumatriptan (positive control)
Trial: 17368154
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg daily, 5 mg for children younger than 12 months) for mean 484.7 days
Trial: 12013585
Drug: Dysport 500
RxNorm normalized name: Dysport 500 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport 500 units (open phase treatment)
Trial: 12013585
Drug: Placebo (open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (open phase treatment)
Trial: 9141920
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid (100 mg/kg, followed by 10 mg.kg‐1.h‐1)
Trial: 8201089
Drug: Fluid infusion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid infusion alone (Group non-HD)
Trial: 3322955
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg plus pirenzepine 100 mg daily
Trial: 27173813
Drug: Sipjeondaebo-tang (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipjeondaebo-tang (3 g, 3 times a day for 4 weeks)
Trial: 24987061
Drug: Cetuximab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (in combination with CAPOX)
Trial: 23342566
Drug: 1.23% APF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% APF gel for 1 minute
Trial: 23342566
Drug: 1.23% APF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% APF gel for 4 minutes
Trial: 23342566
Drug: 1% TiF4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% TiF4 solution for 1 minute
Trial: 18156640
Drug: Olanzapine, risperidone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine, risperidone, and typical antipsychotics
Trial: 12865605
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of citicoline twice per day
Trial: 10225070
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with buprenorphine 0.15 mg
Trial: 10225070
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural analgesia (LEA) with buprenorphine 0.15 mg
Trial: 1909239
Drug: Loreclezole (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loreclezole (targeted plasma level of 1-2 mg/l)
Trial: 28381307
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs after ICH
Trial: 24107831
Drug: Levobupivacaine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 5 mg/mL, 45 mL
Trial: 24107831
Drug: Levobupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 7.5 mg/mL, 30 mL
Trial: 24107831
Drug: Levobupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 7.5 mg/mL mixed with 0.9% NaCl, 30 mL
Trial: 11575416
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg kg(‐1) to a maximum of 25 mg
Trial: 11575416
Drug: Ondansetron 100
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 100 microg kg(‐1) to a maximum of 4 mg
Trial: 2686409
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg twice daily for 14 days
Trial: 2686409
Drug: Ampicillin 500
RxNorm normalized name: ampicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 500 mg four times a day for 14 days
Trial: 28801309
Drug: Cold-pressed turnip
RxNorm normalized name: LEMON OIL, COLD PRESSED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-pressed turnip rapeseed oil (CPTRO) 35 mL for 6-8 weeks
Trial: 28801309
Drug: Butter 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter 37.5 g for 6-8 weeks
Trial: 24398758
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m² for 21 days)
Trial: 24398758
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² for 21 days)
Trial: 20178093
Drug: Cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis extract (20 mg THC)
Trial: 18289159
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with anthelmintic drugs
Trial: 14639535
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 200 mg once daily
Trial: 14639535
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 25 mg once daily
Trial: 14639535
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) 100 mg once daily
Trial: 14639535
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (3TC) 150 mg 2 times/day
Trial: 27211522
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone 20 mg
Trial: 27211522
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone 20 mg plus naltrexone 2.4 mg (simulated crushed ALO-02)
Trial: 27211522
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride for injection)
Trial: 17414980
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg intraoperative dose)
Trial: 11865837
Drug: Pentoxifylline (PXF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PXF) 400 mg three times daily
Trial: 7776987
Drug: 240 ml
RxNorm normalized name: Iron 5 MG/240 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 ml of lactose-hydrolyzed milk containing 2 percent fat
Trial: 7776987
Drug: 240 ml
RxNorm normalized name: Iron 5 MG/240 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 ml of milk containing 2 percent fat and sweetened with aspartame
Trial: 2137976
Drug: Nafarelin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin, 200 micrograms twice daily
Trial: 2137976
Drug: Danazol, 200
RxNorm normalized name: Danazol, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol, 200 mg twice daily
Trial: 25863797
Drug: Daily maximum
RxNorm normalized name: GNP One Daily Maximum Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily maximum respiratory rate (maxRR)
Trial: 25863797
Drug: Daily median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily median respiratory rate (medRR)
Trial: 25863797
Drug: Daily minimum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily minimum respiratory rate (minRR)
Trial: 23261207
Drug: PHAROS Vitesse
RxNorm normalized name: Vitespen
DrugBank: Vitespen (DB06400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHAROS Vitesse neurovascular balloon-expandable stent system plus medical therapy
Trial: 20868456
Drug: Southern regular
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern regular implants and standard ball attachments (control)
Trial: 20868456
Drug: Southern 8-mm-wide
RxNorm normalized name: SOUTHERN FLOUNDER
DrugBank: Flounder (DB10531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern 8-mm-wide implants and large ball attachments
Trial: 20868456
Drug: Neoss regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoss regular implants and Locator attachments
Trial: 20868456
Drug: Southern 8-mm-wide
RxNorm normalized name: SOUTHERN FLOUNDER
DrugBank: Flounder (DB10531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern 8-mm-wide implants and large ball attachments and Neoss regular implants and Locator attachments
Trial: 16705849
Drug: Composite sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite sulfur (tablet) moxibustion plus SASP and MTX
Trial: 11281583
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml MMC applied for 5 minutes
Trial: 11281583
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml MMC applied for 5 minutes
Trial: 9207749
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 6 x 10(8) KML
Trial: 9207749
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 5 x 10(7) KML
Trial: 9207749
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 5 x 10(6) KML
Trial: 9207749
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg
Trial: 2908765
Drug: Lidamidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidamidine (20 mg p.o.)
Trial: 2908765
Drug: Idazoxan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (20 mg p.o.)
Trial: 27399998
Drug: No medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medications (Control)
Trial: 19122958
Drug: 80 percent
RxNorm normalized name: Blended spread 70 to 80 percent fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 percent phenol solution
Trial: 8214494
Drug: Intra-arterial regional
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial regional analgesia with lignocaine 0.5%, 1.5 mg.kg‐1
Trial: 8214494
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional analgesia with lignocaine 0.5%, 3.0 mg.kg‐1
Trial: 3440240
Drug: Radical orchidectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical orchidectomy and chemotherapy for Group I patients
Trial: 3440240
Drug: Orchidectomy, chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchidectomy, chemotherapy, and radiation therapy for Group II patients
Trial: 3440240
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for patients with distant metastases at diagnosis
Trial: 3440240
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment for all 95 children
Trial: 25622243
Drug: Ibuprofen (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1.2 g administered 1 hour before the second tlim trial)
Trial: 25622243
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose administered 1 hour before the second tlim trial)
Trial: 21775979
Drug: Duloxetine (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (14 days treatment)
Trial: 16540949
Drug: Urinary trypsin
RxNorm normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary trypsin inhibitor (5000 units/kg intravenous)
Trial: 12656696
Drug: Omeprazole-based triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based triple therapy
Trial: 7490894
Drug: Self-administered alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered alfentanil via a patient controlled infusion pump
Trial: 7490894
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving alfentanil infusion titrated by anesthesiologists
Trial: 29186989
Drug: EPVL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPVL plus 0.4 mg oral tamsulosin daily (n=236)
Trial: 29186989
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin PO qd (n=222)
Trial: 24284002
Drug: Combined KMC
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined KMC and 24% oral sucrose
Trial: 24284002
Drug: 24% oral
RxNorm normalized name: Entero VU, 24% oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% oral sucrose alone
Trial: 21827441
Drug: 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mcg/kg dexmedetomidine in 100 ml of normal saline over 10 min; 1 mcg/kg/h dexmedetomidine infusion during surgery
Trial: 21827441
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of normal saline over 10 min; 1 ml/kg/h normal saline infusion during surgery
Trial: 17873492
Drug: Bosentan (8-125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (8-125 mg b.i.d.)
Trial: 12424933
Drug: Deferiprone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (75 mg/kg/day in 12 hourly divided doses)
Trial: 12424933
Drug: Standard quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard quinine and doxycycline therapy with placebo
Trial: 8955576
Drug: Nasal corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal corticosteroid treatment
Trial: 1834440
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of ANF 100 micrograms
Trial: 1834440
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ANF 50 micrograms at 1.67 micrograms/min for 30 min
Trial: 29793446
Drug: Propranolol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administration
Trial: 14658256
Drug: Indomethacin administration
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin administration
Trial: 26096582
Drug: Robot-assisted intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted intervention with Paro (30 minutes twice a week for 12 weeks)
Trial: 24924267
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid spray (two pumps, three times daily for 7 days)
Trial: 24924267
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride spray (two pumps, three times daily for 7 days)
Trial: 19317300
Drug: Prolonged heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged heparin infusion
Trial: 19317300
Drug: No post-procedural
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: No post-procedural heparin (control group)
Trial: 17503991
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean endpoint dose = 460 ± 88 mg/day)
Trial: 6841187
Drug: Remotely controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely controlled high-dose-rate intracavitary radiotherapy (30 Gy for high-dose-rate group by 3 fractions with a once a week schedule)
Trial: 6841187
Drug: Manual afterloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual afterloading low-dose-rate therapy (40-60 Gy with one or two fractions)
Trial: 6841187
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (high-dose-rate and low-dose-rate)
Trial: 30620767
Drug: Clinical trials
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trials with new anticancer biological agents
Trial: 30620767
Drug: Clinical trials
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trials with immunotherapeutic drugs
Trial: 31676222
Drug: Odanacatib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (50 mg once per week)
Trial: 26564281
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100-200mg daily)
Trial: 26564281
Drug: Letrozole (2.5-5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5-5mg daily)
Trial: 16428551
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg
Trial: 7931231
Drug: Deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl (10 mg per day for 12 weeks)
Trial: 3146506
Drug: Oral co-dergocrine
RxNorm normalized name: co-dergocrine mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-dergocrine (8.0 mg)
Trial: 3146506
Drug: Intravenous co-dergocrine
RxNorm normalized name: co-dergocrine mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous co-dergocrine (0.9 mg)
Trial: 3146506
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral doses
Trial: 31977270
Drug: D-index-guided early
RxNorm normalized name: MAGNI-GUIDE (B-D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-index-guided early antifungal therapy (DET)
Trial: 31977270
Drug: Empiric antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antifungal therapy (EAT)
Trial: 26630216
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 or 20 mg daily
Trial: 26630216
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 or 20 mg daily
Trial: 26630216
Drug: Lercanidipine-Enalapril combination
RxNorm normalized name: enalapril and lercanidipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine-Enalapril combination treatment
Trial: 25519464
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (58.5 mg/mL)
Trial: 25519464
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (9 mg/mL)
Trial: 20674480
Drug: 7% carbon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% carbon dioxide inhalation
Trial: 10746484
Drug: Trandolapril 4
RxNorm normalized name: trandolapril 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 4 mg daily
Trial: 8770673
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy aimed to correct CA, N=15